NETRIS Pharma will attend the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 07th-10th, 2019). Our team members attending the event will be pleased to meet you for…
NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors Dose-escalation part of study met primary objective Study shows NP137 to have…
NETRIS Pharma will attend the 2018 BIO International Convention event in Boston, MA (June 04th-07th). Our team members attending the event will be pleased to meet you for discussing opportunities…
NETRIS Pharma will attend PEGS 2018 event in Boston, MA (April 30th-May 04th). Our CEO, Pr. Patrick Mehlen, will give a presentation on April 30th within the Oncology stream – Antibodies…
NETRIS Pharma will attend the BIO-Europe Spring 2018 event in Amsterdam, Netherlands (March 12th-14th). Our team members attending the event will be pleased to meet you for discussing opportunities with…
The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…
NETRIS Pharma will attend the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 08th-11th, 2018). Our team members attending the event will be pleased to meet you…
NETRIS Pharma will attend the BIO-Europe 2017 meeting in Berlin, Germany (November 06th-08th). Our team members attending the event will be pleased to meet you for discussing opportunities with potential…
Lyon, France – 21 March 2017 – NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors. NETRIS Pharma, a pioneer in the development of dependence…
NETRIS Pharma announces the approval of Agence Nationale de Sécurité des Médicaments et produits de santé (ANSM) for the clinical evaluation of NP137, its first humanized monoclonal antibody targeting Netrin-1….
